Your browser doesn't support javascript.
loading
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
Zhao, Jiao-Yu; Liu, Si-Ning; Xu, Lan-Ping; Zhang, Xiao-Hui; Wang, Yu; Chen, Yu-Hong; Liu, Kai-Yan; Huang, Xiao-Jun; Mo, Xiao-Dong.
Afiliação
  • Zhao JY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liu SN; Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, 030001, China.
  • Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wang Y; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China.
  • Chen YH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Mo XD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Ann Hematol ; 100(1): 169-180, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33159239
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Terapia de Salvação / Transplante de Células-Tronco Hematopoéticas / Resistência a Múltiplos Medicamentos / Ciclofosfamida / Transplante Haploidêntico / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Terapia de Salvação / Transplante de Células-Tronco Hematopoéticas / Resistência a Múltiplos Medicamentos / Ciclofosfamida / Transplante Haploidêntico / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China